Executive Summary

WE BELIEVE IN COORDINATED ESSENTIALS FOR ADVANCING DNA / RNA VACCINES AND THERAPIES

Delivery technology

Formulation technology

Responsiveness and scale

Pivotal Partnerships

orlance-delivering-rapid-responce

Orlance MACH-1™: Easy, Intuitive ‘Air Gun’ Vaccine Delivery

MACH-1 Maximizes Device Platform
Opportunities for DNA and RNA Vaccines

MACH-1 Uniquely Localizes Dose into Highly Immunogenic Epidermis

Orlance MACH-1 Pipeline

Orlance, Inc. Company Profile

Contact Information

Orlance, Inc.
1124 Columbia St., Suite 300
Seattle, WA 98104
206-792-5510

CEO

Kristyn Aalto
kaalto@orlance.com

Lead Asset Status

Kristyn Aalto
kaalto@orlance.com

Funding

$9.6M Non-Dilutive
(Plus $3M Non-Dilutive Pending)
PreSeed
Seed Raise 2023

Founded

2016

Founders

Kristyn Aalto, CEO, Director
Deborah Fuller, PhD, CTO, Director
James Mullins, PhD, Founder

Partnering Status

Early Partnering, No Current Field Restrictions, Seeking Co-Development